Rodman & Renshaw initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $8 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.